KR100567149B1 - 클라리트로마이신의 0형 결정 - Google Patents

클라리트로마이신의 0형 결정 Download PDF

Info

Publication number
KR100567149B1
KR100567149B1 KR1019997006446A KR19997006446A KR100567149B1 KR 100567149 B1 KR100567149 B1 KR 100567149B1 KR 1019997006446 A KR1019997006446 A KR 1019997006446A KR 19997006446 A KR19997006446 A KR 19997006446A KR 100567149 B1 KR100567149 B1 KR 100567149B1
Authority
KR
South Korea
Prior art keywords
methylerythromycin
type
solvate
prepared
carbomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019997006446A
Other languages
English (en)
Korean (ko)
Other versions
KR20000070220A (ko
Inventor
스팬튼스티븐지
헨리로져에프
릴리데이비드에이
리우지-화
Original Assignee
아보트 러보러터리즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25136084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100567149(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아보트 러보러터리즈 filed Critical 아보트 러보러터리즈
Publication of KR20000070220A publication Critical patent/KR20000070220A/ko
Application granted granted Critical
Publication of KR100567149B1 publication Critical patent/KR100567149B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1019997006446A 1997-01-17 1997-12-19 클라리트로마이신의 0형 결정 Expired - Fee Related KR100567149B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8/785,623 1997-01-17
US08/785,623 1997-01-17
US08/785,623 US5945405A (en) 1997-01-17 1997-01-17 Crystal form O of clarithromycin
PCT/US1997/023607 WO1998031699A1 (en) 1997-01-17 1997-12-19 Crystal form 0 of clarithromycin

Publications (2)

Publication Number Publication Date
KR20000070220A KR20000070220A (ko) 2000-11-25
KR100567149B1 true KR100567149B1 (ko) 2006-04-04

Family

ID=25136084

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019997006446A Expired - Fee Related KR100567149B1 (ko) 1997-01-17 1997-12-19 클라리트로마이신의 0형 결정

Country Status (18)

Country Link
US (1) US5945405A (OSRAM)
EP (1) EP1077988A1 (OSRAM)
JP (3) JP4058114B2 (OSRAM)
KR (1) KR100567149B1 (OSRAM)
CN (1) CN1174991C (OSRAM)
AR (3) AR011077A1 (OSRAM)
AU (1) AU735598B2 (OSRAM)
BR (1) BR9714287A (OSRAM)
CA (4) CA2387356C (OSRAM)
CZ (1) CZ297433B6 (OSRAM)
DE (1) DE97951771T1 (OSRAM)
ES (1) ES2173058T1 (OSRAM)
IL (1) IL130255A0 (OSRAM)
NZ (1) NZ336073A (OSRAM)
TR (1) TR199901578T2 (OSRAM)
TW (1) TW574224B (OSRAM)
WO (1) WO1998031699A1 (OSRAM)
ZA (1) ZA98116B (OSRAM)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
GB9827355D0 (en) * 1998-12-11 1999-02-03 Biochemie Sa Organic compounds
KR100322313B1 (ko) * 1999-10-21 2002-02-06 민경윤 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트
US6627743B1 (en) * 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
PT1254146E (pt) * 1999-12-16 2005-10-31 Teva Pharma Processos de preparacao de polimeros de claritromicina e novo polimorfo iv
FR2802534B1 (fr) * 1999-12-20 2002-02-01 Merial Sas Procede pour preparer et isoler la 9-deoxo-9 (z)- hydroxyiminoerythromycine a
PL356645A1 (en) * 2000-01-11 2004-06-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
AU2578701A (en) 2000-02-29 2001-09-12 Teva Pharma Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
CN1193036C (zh) * 2000-03-15 2005-03-16 韩美药品工业株式会社 制备甲红霉素－克拉霉素ⅱ型晶体的方法
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
KR20030011797A (ko) * 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 맛이 차폐된 과립형 입자
WO2002011768A1 (en) * 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
WO2005039531A1 (en) * 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
KR100408848B1 (ko) * 2001-03-12 2003-12-06 주식회사 씨트리 클래리스로마이신의 정제방법
RU2217160C2 (ru) * 2001-04-20 2003-11-27 Челябинская государственная медицинская академия Способ местного лечения урогенитального хламидиоза у женщин
EP1411899B1 (en) * 2001-08-01 2009-03-11 Novartis AG Taste masking composition
TW200302830A (en) * 2002-01-11 2003-08-16 Chugai Pharmaceutical Co Ltd Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate
CN100427498C (zh) * 2003-03-02 2008-10-22 王凌峰 克拉霉素a型结晶
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1648418A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
EP1648415A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1658034A4 (en) * 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8715727B2 (en) 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
WO2007036951A2 (en) * 2005-08-31 2007-04-05 Alembic Limited Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
NZ571460A (en) 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
DE102007016367A1 (de) 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von Clarithromycin (Form V)
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin
EP2030613A1 (en) 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
US9119769B2 (en) 2011-12-30 2015-09-01 The Curators Of The University Of Missouri Method for transforming pharmaceutical crystal forms
CN103087130B (zh) * 2013-02-06 2015-12-23 浙江国邦药业有限公司 一种克拉霉素晶型转换方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4672109A (en) * 1984-04-06 1987-06-09 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin A derivatives
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS5782400A (en) 1980-11-12 1982-05-22 Taisho Pharmaceut Co Ltd Erythromycin derivative
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
DE3782994T2 (de) * 1986-09-18 1993-04-08 Taisho Pharma Co Ltd Erythromycin-a-derivate und verfahren zu ihrer herstellung.
JPH0755958B2 (ja) * 1986-10-03 1995-06-14 大正製薬株式会社 エリスロマイシンａ誘導体の製造方法
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
JP2526951B2 (ja) * 1986-12-17 1996-08-21 大正製薬株式会社 エリスロマイシンａ誘導体およびその製造方法
JP2751385B2 (ja) * 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンａオキシム及びその塩の製造方法
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
PT915899E (pt) * 1996-07-29 2004-11-30 Abbott Lab Preparacao da forma cristalina ii da eritromicina
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4672109A (en) * 1984-04-06 1987-06-09 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin A derivatives
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions

Also Published As

Publication number Publication date
CZ242699A3 (cs) 1999-11-17
JP5190350B2 (ja) 2013-04-24
AR039667A2 (es) 2005-03-02
US5945405A (en) 1999-08-31
ZA98116B (en) 1998-07-08
CA2419499A1 (en) 1998-07-23
AR039666A2 (es) 2005-03-02
JP2000509725A (ja) 2000-08-02
AU5532698A (en) 1998-08-07
JP2004075689A (ja) 2004-03-11
CN1244869A (zh) 2000-02-16
IL130255A0 (en) 2000-06-01
KR20000070220A (ko) 2000-11-25
EP1077988A1 (en) 2001-02-28
WO1998031699A1 (en) 1998-07-23
BR9714287A (pt) 2000-04-18
CA2277274C (en) 2003-05-27
CA2277274A1 (en) 1998-07-23
CZ297433B6 (cs) 2006-12-13
CA2387361C (en) 2003-05-27
NZ336073A (en) 2001-01-26
DE97951771T1 (de) 2004-07-08
CA2387361A1 (en) 1998-07-23
CA2387356A1 (en) 1998-07-23
JP2009137975A (ja) 2009-06-25
TW574224B (en) 2004-02-01
JP4058114B2 (ja) 2008-03-05
CN1174991C (zh) 2004-11-10
ES2173058T1 (es) 2002-10-16
AU735598B2 (en) 2001-07-12
TR199901578T2 (xx) 1999-09-21
AR011077A1 (es) 2000-08-02
CA2387356C (en) 2003-05-27

Similar Documents

Publication Publication Date Title
US5945405A (en) Crystal form O of clarithromycin
EP0915898B1 (en) Crystal form i of clarithromycin
US6987175B2 (en) Processes for preparing clarithromycin polymorphs
US6599884B2 (en) Processes for preparing clarithromycin polymorphs and novel polymorph IV
JP2004075689A5 (OSRAM)
AU777612B2 (en) Crystal form I of clarithromycin
AU2005203314A1 (en) Processes for preparing clarithromycin polymorphs
ZA200204638B (en) Processes for preparing clarithromycin polymorphs and novel polymorph IV.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20130227

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20140227

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20150227

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20151230

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170329

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170329